Our Technology
The aptamer BC 007 – a non-modified 15mer ssDNA oligonucleotide – is a compound capable of neutralizing functional autoantibodies (AABs) by simple intravenous infusion. It forms the basis of our platform technology and has so far proven to be a safe and effective medication method for autoantibody related diseases.
TechnologyLong Covid Syndrome (LCS)
Promising compassionate use treatments of patients suffering from Long Covid Syndrome (LCS) in summer 2021 indicated that BC 007 is the only drug worldwide that may cure LCS at the moment. We therefore, aim to make BC 007 available on the market as fast as possible for LCS patients.
More about LCSHeart Failure
Clinical trials with heart failure patients are far advanced (completion of phase IIa in 2022) and have so far been extremely successful. In fact, all patients treated with BC 007 feel well and show a clear and significant improvement of their heart ejection fraction. After a re-examination of the results to further verify the positive effects of BC 007, it is expected that a broad phase IIb/III study will commence in 2023.
Heart FailureTest your blood for autoantibodies
Please Note:
Currently, Berlin Cures is getting the Lab prepared for study-related analytic tests. Therefore, effective immediately, Berlin Cures will no longer accept incoming specimens for the measurement of autoantibodies. Please do NOT send us specimens. Thank you for your understanding.
Wir stellen unser Labor um auf kommende Aufgaben, die mit klinischen Studien im Zusammenhang stehen. Daher können wir ab sofort keine Blutproben zur Autoantikörperbestimmung mehr annehmen. Bitte senden Sie uns kein Serum zu. Wir danken für Ihr Verständnis.
